|

FT819 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Fate Therapeutics1

Indications

  • Idiopathic Inflammatory Myositis (IIM)1
  • Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)1
  • Systemic Sclerosis (SSc)1
  • Systemic Lupus Erythematosus (SLE)1
  • Lupus1

Fullerton, California1 trial

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Providence Medical Foundation

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.